NEW YORK, March 13, 2013 /PRNewswire/ --
Today, Investors Alliance announced new research reports highlighting Kellogg Company (NYSE:K), General Mills, Inc. (NYSE:GIS), Gilead Sciences, Inc. (NASDAQ:GILD), Celgene Corporation (NASDAQ:CELG) and The Coca-Cola Company (NYSE: KO). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
Kellogg Company Research Report
Kellogg, best known for its ready-to-eat cereals, has since expanded to produce more food items like cookies, crackers, and potato chips, among others partly through its many acquisitions in the past. It's most recent purchase, Pringles, put the company in second place in the savory snack market behind Lays and Doritos maker PepsiCo. Motley Fool says both Kellogg and PepsiCo should benefit from rising income and increased urbanization outside the US, as demand for convenient pre-packaged food is likely to increase exponentially. In addition, Kellogg forged another deal for international growth with Singapore-based Wilmar International, which will manufacture, sell, and distribute Kellogg's brands in China. However, Zacks maintains its "neutral" rating on the company despite robust numbers, citing sluggish sales on its legacy cereals business and declines in its European business. Nevertheless, Kellogg's brand positioning, geographic diversity, cost-cutting, and the Pringles acquisition should counter these negatives. The Full Research Report on Kellogg Company - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.Investors-Alliance.com/r/full_research_report/f3a1_K]
General Mills, Inc. Research Report
The Street rating the company as a "buy," citing revenue growth, good cash flow from operations, net income growth, among others, which outweigh its "generally high" debt management risk. General Mills started reducing its workforce and production costs of other products amid acquisitions and growing wholesale orders to avoid increasing end prices and keep up with expected revenues. However, analysts at Goldman Sachs are not optimistic with the company's new cereal lineup this year, and won't make up the subpar numbers elsewhere. In addition, its Yoplait yoghurt is underperforming despite the popularity of Greek yogurt. The Full Research Report on General Mills, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.Investors-Alliance.com/r/full_research_report/5ea3_GIS]
Gilead Sciences, Inc. Research Report
Gilead has been getting the attention of analysts, investors, medical professionals and patients who have found hope in the world's largest maker of HIV drugs. During the last week of August 2012, the company launched the HIV drug, Stribilid or the "quad," which is a combination of four different medicines. Although the drug only had a few weeks of sales during Q3, the figures seem to be picking up. While sales of HIV drugs are continuing to increase, analysts and investors have other reasons to be bullish about the company. Gilead's acquisition of Pharmasset Inc., along with its highly coveted Sofusbivir hepatitis C drug, may help the company generate an additional $3.8 billion by 2020. The company is also investing on blood cancer drugs, and has reportedly spent $1.2 billion on blood cancer drugs. Gilead is still looking at great potentials to expand its offerings, and it is targeting to meet the significantly growing market demand for blood cancer treatments. Celgene's executives and stakeholders are delighted to celebrate a 14% increase in net product sales during Q4. Celgene's full year adjusted net income for 2012 reached $2.1 billion, a solid growth performance that accounts for the company's global market share. The Full Research Report on Gilead Sciences, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.Investors-Alliance.com/r/full_research_report/5969_GILD]
Celgene Corporation Research Report
Celgene's net product sales for Abraxane and Vidaza saw a 3% increase, and a remarkable 17% increase for Revlimid. Celgene's Revlimid is probably one of its products which have been helping the company maintain its solid performance. Some analysts say that Celgene is still a good buy because of the catalysts that will drive the company to its $12 billion annual revenue by 2017.
The most important factor that investors must focus on is each company's portfolio. Celgene offers products which are sought after by a large market. The size of the market and the growing demand for treatments make the perfect catalyst. While the risks for developing breakthrough treatments are unarguably high, Celgene seems able to survive any drug trial failure with the help of their excellent contingency plans. The Full Research Celgene Corporation - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.Investors-Alliance.com/r/full_research_report/d457_CELG]
The Coca-Cola Company Research Report
One of the Coca-Cola Company's strategies was to launch an anti-obesity ad campaign, but it was duly met with much criticism. Another strategy that Coca-Cola is using is to expand its portfolio of non-carbonated drinks. At present, Coca-Cola has a leading position in the juices or still beverages category with Minute Maid, Simply and POWERade. To add to this line of products, the company has purchased stakes in Fair Oaks Farms Brands, LLC, a company that produces high-protein milk shakes, creating a new portfolio of healthy beverages with high growth potential. The Full Research Report on The Coca-Cola Company - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.Investors-Alliance.com/r/full_research_report/ed8f_KO]
Consider Investors Alliance
Tired of hearing about the latest, greatest trade opportunity... only to realize that the ship has long sailed? You need a strong, informative community in your arsenal. Join the group that has been consistently identifying momentous situations as they develop - long before they become the next top news on major financial networks.
Contact: Patricia Byers